Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Meanwhile, PI3K is positively correlated with PKB and PKB is positively correlated with mTOR in NPC. 30582216 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 AlteredExpression disease BEFREE Our studies are the first to demonstrate that reduced CTGF as an unfavorable prognosis factor mediates the activation of miR-18b, an oncomir directly suppresses CTGF expression, by PI3K/AKT/C-Jun and C-Myc and promotes cell growth of NPC. 23681229 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Galangin effects on apoptosis and S-phase arrest in NPC cells are mediated via interfering with the PI3K-AKT signaling pathway in a p53-independent manner. 29491062 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Downregulation of monocarboxylate transporter 1 inhibits the invasion and migration through suppression of the PI3K/Akt signaling pathway in human nasopharyngeal carcinoma cells. 29882205 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma. 28720063 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. 24041865 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Thus, DAB2IP suppresses growth and metastasis of NPC probably by targeting PI3K/Akt pathway, and may act as a hopeful therapeutic target for NPC. 28586035 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Moreover, our finding emphasizes the association of PIK3CA gene amplification with worse prognosis in nasopharyngeal carcinoma. 19735264 2009
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE These findings show that mutated PI3K may be involved in the NPC tumorigenesis but does not affect patient's prognosis, suggesting that PI3K is a potential target in NPC for targeted therapeutics using specific kinase inhibitors. 19012001 2009
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 AlteredExpression disease BEFREE The results of the present study indicate that high levels of ROCK1 and PIK3CA expression may be associated with advanced stages in NPC. 28450943 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma. 30944308 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 AlteredExpression disease BEFREE In conclusion, TCS radiosensitized NPC <i>in vitro</i> and <i>in vivo</i> via downregulation of PI3K pathways and the upregulation of cleaved caspase-3. 30402158 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE These data suggest that ZIP4 induces the EMT and promotes migration and invasion via the PI3K/Akt signaling pathway in NPC. 31383854 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Annexin A1-suppressed autophagy promotes nasopharyngeal carcinoma cell invasion and metastasis by PI3K/AKT signaling activation. 30459351 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is important in nasopharyngeal carcinoma (NPC) pathogenesis. 19276680 2009
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 GeneticVariation disease BEFREE Profiling of somatic mutations and copy number variations (CNV) in NPC tumors identified alterations in RTK/RAS/PI3K, NOTCH, DNA repair, chromatin remodeling, cell cycle, NF-κB, and TGF-β pathways. 31328403 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE The findings implied that PIK3CA may be a putative oncogene involved in the tumorigenesis of NPC. 15586224 2005
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Exome and RNA sequencing data from new EBV-positive NPC models also highlight the importance of PI3K pathway aberrations in NPC. 31521748 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 AlteredExpression disease BEFREE The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via the regulation of the PI3K/Akt signalling pathway in NPC. 25351620 2015
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE In conclusion, these results indicate that camptothecin treatment may inhibit the viability of NPC cells and aggressiveness by regulating the TGF-β-induced PI3K/AKT signaling pathways, which in turn may be a potential molecular target for the treatment of NPC. 29963130 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE In conclusion, this integrative pharmacology-based analysis revealed the anti-NPC effects of RO might be related to its regulatory impact via the PI3K-AKT signaling pathway, the Wnt signaling pathway, and the cAMP signaling pathway by targeting VEGFA, TP53, and HSPA8. 30936832 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE This suggests that PI3K/AKT pathway has an important role in the induction and maintenance of CSC properties in NPC. 26568302 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE It may also contribute to the development of new therapeutic strategies to block the PI3K/AKT pathway in NPC cancer cells. 20927779 2010
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 Biomarker disease BEFREE Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. 30374682 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.400 GeneticVariation disease BEFREE Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. 27876891 2016